Ocnil 400 mg/g Powder for Use in Drinking Water

국가: 영국

언어: 영어

출처: VMD (Veterinary Medicines Directorate)

유효 성분:

Lincomycin

제공처:

Vetpharma Animal Health, S.L

ATC 코드:

QJ01FF02

INN (International Name):

Lincomycin

약제 형태:

Powder for use in drinking water

처방전 유형:

POM-V - Prescription Only Medicine – Veterinarian

치료 그룹:

Chickens, Pigs

치료 영역:

Antimicrobial

승인 상태:

Authorized

승인 날짜:

2017-07-19

제품 특성 요약

Revised: August 2022
AN: 02021/2021 & 02022/2021
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
OCNIL 400 mg/g powder for use in drinking water
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram contains:
ACTIVE SUBSTANCE:
Lincomycin
...................................................................................400
mg
_(equivalent to 450 mg of lincomycin hydrochloride)_
EXCIPIENTS:
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Powder for use in drinking water.
White powder, inodorous and without lumps.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs and Chickens.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
PIGS
Treatment
and
metaphylaxis
of
enzootic
pneumonia
caused
by
_Mycoplasma _
_hyopneumoniae_.
The presence of the disease in the group must be established before
the product is
used.
CHICKENS: Treatment and metaphylaxis of necrotic enteritis caused by
_Clostridium _
_perfringens._
The presence of the disease in the group must be established before
the product is
used.
4.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
Revised: August 2022
AN: 02021/2021 & 02022/2021
Page 2 of 7
Do not administer, and do not allow access to water containing
lincomycin, to
rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants as
this could result
in severe gastrointestinal disturbances.
Do not use in cases of resistance to lincosamides.
Do not use in cases of hepatic dysfunction.
4.4
SPECIAL WARNINGS FOR TARGET SPECIES
Medicated drinking water uptake can be affected by the severity of the
disease. In
case of insufficient uptake of water, pigs should be treated
parenterally.
The susceptibility of _Mycoplasma hyopneumoniae_ to antimicrobial
agents is difficult
to test _in vitro_ owing to technical constraints. In addition, there
is a lack of clinical
breakpoints for both _ M. hyopneumoniae_ and _ C. perfringens_. Where
possible,
therapy should be based on local (regional